Posttransplantation prophylaxis with primary high‐dose hepatitis B immunoglobulin monotherapy and complementary preemptive antiviral add‐on
暂无分享,去创建一个
H. Lee | Y. Chung | G. Song | Sung‐Gyu Lee | Y. Lim | D. Jung | Shin Hwang | C. Ahn | Ki‐Hun Kim | D. Moon | T. Ha | Heung-Bum Oh
[1] C. Ahn,et al. An increase in deceased donor incidence alleviated the need for urgent adult living donor liver transplantation in a Korean high-volume center. , 2010, Transplantation proceedings.
[2] H. Lee,et al. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. , 2010, Journal of hepatology.
[3] Y. Sohn,et al. [Analysis of clinical characteristics and S gene mutation of hepatitis B virus (HBV) in patients with hepatitis B surface antigen RIA negative and HBV DNA positive]. , 2009, The Korean journal of laboratory medicine.
[4] S. Saab,et al. Decision analysis model for hepatitis B prophylaxis one year after liver transplantation , 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[5] Vincent Leroy,et al. Assessment of selective real-time PCR for quantitation of lamivudine and adefovir hepatitis B virus-resistant strains and comparison with direct sequencing and line probe assays. , 2009, Journal of virological methods.
[6] E. Yu,et al. Characterization of histopathological features that differentiate hepatitis B virus infection from acute cellular rejection , 2009 .
[7] G. Song,et al. Prevention of hepatitis B recurrence after living donor liver transplantation: Primary high‐dose hepatitis B immunoglobulin monotherapy and rescue antiviral therapy , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[8] Karen G. Smith,et al. Hepatitis B immunoglobulin and Lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[9] D. Samuel,et al. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. , 2008, Gastroenterology.
[10] Young-Jo Lee,et al. Direct detection of lamivudine-resistant hepatitis B virus mutants by a multiplex PCR using dual-priming oligonucleotide primers. , 2008, Journal of virological methods.
[11] S. Locarnini. Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure , 2008, Hepatology international.
[12] J. Joh,et al. Recurrence of hepatitis B is associated with cumulative corticosteroid dose and chemotherapy against hepatocellular carcinoma recurrence after liver transplantation , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[13] A. Lok,et al. Antiviral therapy for pre‐ and post‐liver transplantation patients with hepatitis B , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[14] S. Thung. Histologic findings in recurrent HBV , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[15] R. Gish,et al. Hepatitis B in liver transplant recipients , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[16] Y. Liu,et al. Evolution of multi‐drug resistant hepatitis B virus during sequential therapy , 2006, Hepatology.
[17] Sung‐Gyu Lee,et al. Five‐year follow‐up of a hepatitis B virus‐positive recipient of hepatitis B surface antigen‐positive living donor liver graft , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[18] W. Roberts,et al. The analytic sensitivity and mutant detection capability of six hepatitis B surface antigen assays. , 2006, American journal of clinical pathology.
[19] C. Wai,et al. Prophylactic strategies for hepatitis B patients undergoing liver transplant: A cost‐effectiveness analysis , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[20] C. W. Kim,et al. Hepatitis B Virus Genotype C Prevails Among Chronic Carriers of the Virus in Korea , 2005, Journal of Korean medical science.
[21] S. Fan,et al. Liver transplantation for chronic hepatitis B with lamivudine‐resistant YMDD mutant using add‐on adefovir dipivoxil plus lamivudine , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[22] D. Samuel,et al. Management of the hepatitis B virus in the liver transplantation setting: A European and an American perspective , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[23] Huiling Yang,et al. Cross-Resistance Testing of Next-Generation Nucleoside and Nucleotide Analogues against Lamivudine-Resistant HBV , 2005, Antiviral therapy.
[24] A. Lok. Liver transplantation for patients with lamivudine‐resistant HBV: What is the optimal prophylactic strategy? , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[25] F. Azorin,et al. Adefovir Dipivoxil Therapy in Liver Transplant Recipients With Lamivudine-Resistant Hepatitis B Virus , 2005 .
[26] S. Cotler,et al. Management of hepatitis B in liver transplant patients. , 2005, Journal of clinical gastroenterology.
[27] J. L. Lucena de la Poza,et al. Adefovir dipivoxil therapy in liver transplant recipients with lamivudine-resistant hepatitis B virus. , 2005, Transplantation proceedings.
[28] D. Samuel,et al. Evolving strategies to prevent HBV recurrence , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[29] G. Tisone,et al. LOW-DOSE HEPATITIS B IMMUNOGLOBULIN GIVEN “ON DEMAND” IN COMBINATION WITH LAMIVUDINE: A HIGHLY COST-EFFECTIVE APPROACH TO PREVENT RECURRENT HEPATITIS B VIRUS INFECTION IN THE LONG-TERM FOLLOW-UP AFTER LIVER TRANSPLANTATION , 2004, Transplantation.
[30] S. Cheung,et al. Fibrosing cholestatic hepatitis secondary to precore/core promoter hepatitis B variant with lamivudine resistance: Successful retransplantation with combination adefovir dipivoxil and hepatitis B immunoglobulin , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[31] D. Samuel,et al. HBV DNA persistence 10 years after liver transplantation despite successful anti‐HBS passive immunoprophylaxis , 2003, Hepatology.
[32] M. Manns,et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. , 2002, Gastroenterology.
[33] I. Mushahwar,et al. Immunoassay detection of hepatitis B surface antigen mutants , 1999, Journal of medical virology.
[34] J. Roberts,et al. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin , 1998, Hepatology.
[35] A. Lok,et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis , 1998, Hepatology.
[36] T. Berg,et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high‐dose hepatitis B immune globulin after liver transplantation , 1998, Hepatology.
[37] M. Manns,et al. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis , 1996, Hepatology.
[38] E. Tanzi,et al. Emergence of hepatitis B virus S gene mutant in a liver transplant recipient , 1995, Journal of medical virology.
[39] R Williams,et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis , 1991, Hepatology.
[40] A. Zuckerman,et al. Vaccine-induced escape mutant of hepatitis B virus , 1990, The Lancet.
[41] A. Zuckerman,et al. HEPATITIS B VARIANT IN EUROPE , 1988, The Lancet.